AzTrials
AzTrials

Ischaemic Type Biliary LesionPhase 3HECLANCT00908245

Ischemic Preconditioning in Major Hepatectomy

A Phase 3 study testing Preconditioning ischemia in people with Ischaemic Type Biliary Lesion, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To evaluate the accuracy of ischemic preconditioning (IPC) as a protective maneuver against ischemia/reperfusion lesion in patients undergoing major liver resection with intermittent portal triad Clamping (IPTC). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Ischaemic Type Biliary Lesion
What is being tested?
Preconditioning ischemia
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
81 participants
Where
1 siteFrance
Study dates
Sep 2003to Dec 2008
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • patients' age ≥ 18 years old,
  • liver resection of 3 segments (as described by Couinaud) or more,
  • posterior lesionectomy (segment VI and VII),
  • liver resection only or associated with a primary digestive or biliary tumor.
  • Portal vein embolisation allowed

Who cannot join

  • Patients with cirrhosis,
  • synchronous radiofrequency or cryotherapy ablation,
  • undergoing segmentectomy,
  • left lateral lesionectomy or laparoscopic liver resection,
  • pregnant women

Trial locations and contacts

1 site in 1 country.

France1 site
  • Hopital Cochin

    Paris, 75014

Other trials in France

About this study

Official title: Evaluation of Ischemic Preconditioning in Patients Undergoing Major Liver Resection With Intermittent Pedicular Clamping: A Multicentric Randomized Trial

To evaluate the accuracy of ischemic preconditioning (IPC) as a protective maneuver against ischemia/reperfusion lesion in patients undergoing major liver resection with intermittent portal triad Clamping (IPTC).

Summary Background Data: For sake of safety and to avoid excessive blood loss during parenchymal transection, vascular inflow occlusion is an effective trick but may cause ischemic damage to the remnant liver and can lead to liver failure in case of chronic liver disease. IPTC has been proven to be superior to continuous hepatic pedicle clamping as it preserve liver remnant from severe ischemia/reperfusion lesion, so does IPC. Yet, if IPC is beneficial if liver resection is performed under IPTC has never been demonstrated in a randomised controlled trial (RCT). The investigators designed a RCT to assess the impact of IPC in patient undergoing major liver resection with intermittent vascular inflow occlusion.

Read the detailed description

This is a prospective controlled trial, conducted between January 2005 and December 2007. Three centres specialized in hepatobiliary surgery (Cochin hospital (Paris, France), BEAUJON hospital (Clichy, France) and PONTCHAILLOU Hospital (Rennes, France)) participated to this study, which has been initiated by the department of hepatobiliary surgery and liver transplantation of the Cochin hospital. The protocol was approved by ethics committees of each participating centres and an informed consent was obtained from each patients before they were enrolled. Eighty seven patients were randomized to either receive ischemic preconditioning prior to liver resection under intermittent pedicular clamping or not. Ischemic preconditioning was performed through a sequence of 10 minutes vascular inflow occlusion and 10 minutes of reperfusion prior to intermittent pedicular clamping. Intermittent pedicular clamping was conducted through a sequence of 15 minutes of vascular inflow occlusion and 5 minutes of reperfusion. The randomization process which was centralized was held in the operating room after inclusion criteria had been check and exclusion criteria ruled out. Inclusion criteria were: patients' age (≥ 18 years old), liver resection of 3 segments (as described by Couinaud) or more, posterior lesionectomy (segment VI and VII), liver resection only or associated with a primary digestive or biliary tumor. Exclusion criteria : Patients with cirrhosis, synchronous radiofrequency or cryotherapy ablation, undergoing segmentectomy, left lateral lesionectomy or laparoscopic liver resection were excluded from further analysis as well as pregnant women.

Anaesthetic protocol:

Patients' status was evaluated by the ASA (American Society of Anaesthesiology) scoring system. Surgical procedure was conducted under low central venous pressure (5cm H2O) to avoid excessive bleeding from suprahepatic veins backflow.13 Patients' anaesthesia was performed using a single protocol that was common to all participating centres. Patients in whom this protocol was contraindicated due to medical reasons were excluded. A standardized general anesthesia using thiopental, sufentanil, atracurium and sevoflurane was applied throughout the study period. Mechanical ventilation was carried out using 50 % oxygen in nitrous oxide and was adjusted to keep end-tidal PCO2 between 4.7 and 6.0 kPA. Intra-venous cefazolin (Cephazolin, PANPHARMA laboratory, FOUGERES, France) was administered for antibioprophylaxy. An arterial line was inserted for arterial pressure monitoring and blood sampling. Central venous pressure was not consistently maintained below a predetermined level. Intraoperative Ringer lactate infusion was limited to the minimum, practically below 500 mL, until parenchymal resection was completed. Following liver resection, hydroxyethyl starch 130 (Voluven, Fresenius laboratory, SEVRES, France), 20 mL/kg, was infused in one hour. Thereafter, additional hydroxyethyl starch, fresh frozen plasma, red blood cell packs were administered as indicated by urinary output, hemodynamics, and biological data. Thresholds for blood transfusion were a hemoglobin level of 7g/dL for healthy patients 64 years of age or under, and 9 g/dL for patients 65 years of age or over and/or with preexisting cardiopulmonary disease (1).

Surgical protocol:

All of the patients included in this study were operated in high volume centres by senior surgeons specialized in hepatobiliary surgery. Major resection was defined as resection of 3 or more liver segment as described by Couinaud. Ischemic preconditioning was performed through a sequence of 10 minutes vascular inflow occlusion and 10 minutes of reperfusion prior to intermittent pedicular clamping. Intermittent pedicle clamping was conducted through a sequence of 15 minutes of vascular inflow occlusion and 5 minutes of reperfusion. Intermittent clamping was used during the whole parenchyma transection process. During ischemic preconditioning the liver left in native position to avoid ischemic process due to compression. Surgical liver biopsies were performed before after interruption of the vascular inflow. The samples were all collected in the same centre (Cochin Hospital) for histological and molecular biological analysis. The device used for clamping was left to the surgeon's discretion (Tourniquet or vascular clamp) but had to be the same for both preconditioning and clamping. The technique used for parenchymal liver transection was left to the surgeon's discretion as well as haemostasis and BILIOSTASIS techniques which were performed using bipolar forceps, metallic clips or ligation depending on vessels or bile ducts size. Devices used for parenchymal transection and haemostasis/BILIOSTASIS techniques were recorded in the preoperative data collection form. Postoperative drainage of the abdominal cavity was left to the surgeon's discretion but was collected in the data sheet. All complications occurring during surgery were collected as well as blood loss, blood transfusion and fluid infusion.

Patient's follow-up and data collection:

Patients' follow-up was 3 months and was initiated the day before surgery (Di). Given that primary hypothesis was a 50% reduction of transaminases (AST, ALT) level on postoperative day 1 in the preconditioning group, blood samples were collected on all patients on Di and POD1 for transaminases measurement. All of these samples were collected in a unique biochemistry laboratory (Hospital Cochin) to avoid inter laboratory variations. Besides these two samples, each centres conducted a regular biological follow-up of patients on a previously established schedule which was common to all centres. Biological assessment was performed on blood samples collected on Di and POD 1, 3, 5, 7, 14 and 28. Blood samples were tested for liver biochemistry (AST, ALT, PAL, GGT, BT and BC), prothrombin time, factor V, blood cells count (red blood cells, white blood cells and platelets) and albumine. Clinical examination was performed every day by the senior surgeon in charge of the patients until they were discharge from hospital, as well as on POD 15, POD 30 (5 days) and POD 90 (10 days). All impaired outcomes were noted in the data sheets. Surgical complications collected were: Intra abdominal bleeding, biliary fistula, vascular complication, intra abdominal abscess, wound infection and reintervention. Medical complication collected were: Infection (urinary tract, lung, catheter) liver dysfunction, liver failure, ascitis, pleural fluid effusion necessitating a drainage or not. Postoperative morbidity and mortality were defined as any impaired surgical or medical outcome or death occurring within POD 90, respectively. When hospital readmission was required patients where hospitalised in the surgical department. Finally histological analysis of the liver samples collected at surgery was reviewed by a single pathologist who was unaware of any clinical data.

Statistical analysis:

The analysis was performed in intention-to-treat. The sample size calculation was based on the primary endpoint postoperative (POD1) aspartate aminotransferase (ALT). According to previous data (ref 4-7,9,10 protocol), the sample size calculation was performed with the expectation of a 50% difference in postoperative serum ALT level with a level of statistical significance of 0.05 and a power of 0.80, using a two-tailed t-test. This calculation indicated to include 38 patients in each group. Modification of ALT was also quantified as the difference between Di and POD 1. Demographic data, baseline characteristics, and surgical data are summarized by groups using descriptive statistic. Categorical variables are expressed as numbers (percentages) and comparisons between groups were performed by the chi-square test or Fisher exact test, when needed. Continuous variables are expressed as mean (standard deviation of the mean (sd)) and were compared using two-tailed t-test. Analyses were performed using SAS software, version 9.1, SAS institute inc, Cary, North Carolina.

Being tested
Control, Preconditioning ischemia
Keywords
Preconditioning, Hepatectomy, Clamping

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ControlProcedure or surgery

    Also called Surgery without preconditioning surgery

    Surgery without preconditioning surgery

  • Preconditioning ischemiaProcedure or surgery

    Also called Surgery with a preconditioning ischemia

    Surgery with a preconditioning ischemia

Study groups in NCT00908245
Study groupRoleWhat they receive
PreconditioningExperimentalSurgery with ischemic preconditioning
Receives: Procedure: Preconditioning ischemia
ControlActive comparatorSurgery without preconditioning ischemia
Receives: Procedure: Control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary outcome was a 50% reduction of transaminases (AST, ALT) level on postoperative day 1 in the preconditioning group.

    Measured: 24 hours

Secondary outcomes (3)
  1. Surgical mortality during the postoperative 3 months

    Measured: 3 months

  2. Surgical and medical morbidity during the postoperative 3 months

    Measured: 3 months

  3. Biological follow up during 3 months

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 May 2009 (estimated)
  2. Study startSep 2003
  3. Primary completionJun 2007
  4. Study completionDec 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
81 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00908245
Sponsor's protocol ID
AOR01010
Acronym
HECLA
Status last verified
Sep 2025
First submitted
22 May 2009
Last updated
20 Nov 2025
Results posted
No
Data monitoring committee
No

Publications

  • Scatton O, Zalinski S, Jegou D, Compagnon P, Lesurtel M, Belghiti J, Boudjema K, Lentschener C, Soubrane O. Randomized clinical trial of ischaemic preconditioning in major liver resection with intermittent Pringle manoeuvre. Br J Surg. 2011 Sep;98(9):1236-43. doi: 10.1002/bjs.7626. Epub 2011 Jul 11.

    PubMed 21809337

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Preconditioning ischemia in people with Ischaemic Type Biliary Lesion, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The primary outcome was a 50% reduction of transaminases (AST, ALT) level on postoperative day 1 in the preconditioning group. (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00908245, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in